Shanghai-based Wuxi AppTec reported strong first-half earnings driven by demand for weight-loss and diabetes drug research and significant growth in its US business.
Key facts
- •Wuxi AppTec's net profit reached 11.08 billion yuan, a 33.7% year-on-year increase.
- •Total revenue for the first half of 2026 was 28.9 billion yuan, up 38.9%.
- •US sales grew to 22.28 billion yuan, representing 77% of the company's total revenue.
- •The company's Hong Kong-traded shares have risen about 62% year to date.
- •Chairman and CEO Li Ge stated the company achieved strong growth across revenue, profit, and cash flow.
Wuxi AppTec, Asia’s largest contract pharmaceutical research provider, reported a 33.7% increase in net profit for the first half of 2026, reaching 11.08 billion yuan (US$1.64 billion). The results exceeded analyst expectations, which had projected a 14.5% increase. The company attributed the growth to strong commercial momentum in client drug programs, particularly those related to diabetes and weight-loss treatments.
By the numbers
Revenue and US Market Performance
The company generated 28.9 billion yuan in total revenue during the first half of the year, representing a 38.9% increase compared to the same period last year. Sales within the United States were a major contributor, climbing to 22.28 billion yuan from 14.24 billion yuan in the previous year. US-based revenue now accounts for approximately 77% of the company's total revenue.
Market Response
Following the earnings announcement, Wuxi AppTec shares traded in Hong Kong rose 1.37% to HK$162.90 on Monday. The stock has seen a year-to-date increase of approximately 62%. On the same day, the Hang Seng Index, Hong Kong’s stock benchmark, rose 0.48%.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by SCMP Business.
